Search

Your search keyword '"Ostergren, J"' showing total 249 results

Search Constraints

Start Over You searched for: Author "Ostergren, J" Remove constraint Author: "Ostergren, J"
249 results on '"Ostergren, J"'

Search Results

2. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme

4. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

5. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

6. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis

7. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis

8. ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

9. [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD]

10. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

11. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis

12. Рекомендации Европейского общества кардиологов по диагностике и лечению заболеваний периферических артерий

13. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)

14. Where Are We With the Management of Hypertension? From Science to Clinical Practice

15. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text

16. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

17. Рекомендации по лечению сахарного диабета, преддиабета и сердечно-сосудистых заболеваний Рабочая группа по диабету и сердечно-сосудистым заболеваниям Европейского общества кардиологов и Европейской ассоциации по изучению диабета

19. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

21. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

22. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)

23. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

24. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study

26. Regression of left ventricular hypertrophy in human hypertension with irbesartan

27. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol

28. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

30. GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES

44. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.

49. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

50. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM Low-Left Ventricular Ejection Fraction Trials.

Catalog

Books, media, physical & digital resources